Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer
| Autor: | Olivia Joan Adams, Stephan von Gunten, Heinz Läubli, Michal A. Stanczak |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
medicine.medical_treatment 610 Medicine & health Biology Biochemistry 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Immune system Cancer immunotherapy Neoplasms medicine Immune Tolerance Humans Sialic Acid Binding Immunoglobulin-like Lectins SIGLEC Cancer Immunotherapy respiratory system medicine.disease Immunity Innate N-Acetylneuraminic Acid Sialic acid 030104 developmental biology chemistry 030220 oncology & carcinogenesis Cancer research N-Acetylneuraminic acid |
| Zdroj: | Adams, Olivia Joan; Stanczak, Michal A; von Gunten, Stephan; Läubli, Heinz (2018). Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer. Glycobiology, 28(9), pp. 640-647. Oxford University Press 10.1093/glycob/cwx108 |
| DOI: | 10.1093/glycob/cwx108 |
| Popis: | Changes in sialic acids in cancer have been observed for many years. In particular, the increase of sialoglycan density or hypersialylation in tumors has been described. Recent studies have identified mechanisms for immune evasion based on sialoglycan interactions with immunoregulatory Siglec receptors that are exploited by tumor cells and microorganisms alike. Siglecs are mostly inhibitory receptors similar to known immune checkpoints including PD-1 or CTLA-4 that are successfully targeted with blocking antibodies for cancer immunotherapy. Here, we summarize the known changes of sialic acids in cancer and the role Siglec receptors play in cancer immunity. We also focus on potential ways to target these Siglec receptors or sialoglycans in order to improve anti-cancer immunity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|